BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12901229)

  • 1. Polymer-protein and polymer-drug conjugates in cancer therapy.
    Thanou M; Duncan R
    Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer conjugates: nanosized medicines for treating cancer.
    Vicent MJ; Duncan R
    Trends Biotechnol; 2006 Jan; 24(1):39-47. PubMed ID: 16307811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG conjugates in clinical development or use as anticancer agents: an overview.
    Pasut G; Veronese FM
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1177-88. PubMed ID: 19671438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
    Duncan R; Vicent MJ; Greco F; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S189-99. PubMed ID: 16113096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.
    Lukyanov AN; Torchilin VP
    Adv Drug Deliv Rev; 2004 May; 56(9):1273-89. PubMed ID: 15109769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer conjugates as anticancer nanomedicines.
    Duncan R
    Nat Rev Cancer; 2006 Sep; 6(9):688-701. PubMed ID: 16900224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates?
    Mero A; Pasut G; Dalla Via L; Fijten MW; Schubert US; Hoogenboom R; Veronese FM
    J Control Release; 2008 Jan; 125(2):87-95. PubMed ID: 18031860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and development of polymer conjugates as anti-angiogenic agents.
    Segal E; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
    Greco F; Vicent MJ
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
    Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
    Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemistry. Nanomaterials for drug delivery.
    Hubbell JA; Chilkoti A
    Science; 2012 Jul; 337(6092):303-5. PubMed ID: 22822138
    [No Abstract]   [Full Text] [Related]  

  • 12. PEGylated polymers for medicine: from conjugation to self-assembled systems.
    Joralemon MJ; McRae S; Emrick T
    Chem Commun (Camb); 2010 Mar; 46(9):1377-93. PubMed ID: 20162127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymer conjugates. Pharmacokinetic considerations for design and development.
    Duncan R; Spreafico F
    Clin Pharmacokinet; 1994 Oct; 27(4):290-306. PubMed ID: 7834965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle technologies for cancer therapy.
    Alexis F; Pridgen EM; Langer R; Farokhzad OC
    Handb Exp Pharmacol; 2010; (197):55-86. PubMed ID: 20217526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer therapeutics: concepts and applications.
    Haag R; Kratz F
    Angew Chem Int Ed Engl; 2006 Feb; 45(8):1198-215. PubMed ID: 16444775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation, successful approach to drug delivery.
    Veronese FM; Pasut G
    Drug Discov Today; 2005 Nov; 10(21):1451-8. PubMed ID: 16243265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New possibilities of application of multifunctional polymers and polymer conjugates.
    Pluta J; Karolewicz B
    Acta Pol Pharm; 2003; 60(3):211-4. PubMed ID: 14556491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.